Screener
Adaptive Biotechnologies ADPT Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Immune Medicine Business | $3.78M-56.6% | $9.79M+34.0% | $37.19M+315% | $8.94M+13.1% | $8.72M-5.7% | |
| Mrd Business | $67.09M+53.5% | $61.89M+54.1% | $56.79M+51.6% | $49.94M+41.5% | $43.72M+34.0% | |
| Revenue by Product | ||||||
| Collaboration Revenue | $0-100% | $0-100% | $33.74M+861% | $3.94M+124% | $3.6M-23.2% | |
| Regulatory Milestone Revenue | $9M+100% | $3M— | $6.5M+30.0% | $5.5M+83.3% | $4.5M0.0% | |
| Service And Licensing Revenue | $3.78M-35.3% | $5.84M+16.9% | $5.84M+16.9% | $5.84M+16.9% | $5.84M+16.9% | |
| Service | $58.09M+48.1% | $58.89M+46.7% | $50.29M+54.9% | $44.44M+37.6% | $39.22M+39.4% |
FAQ
- How does Adaptive Biotechnologies break its business down?
- Adaptive Biotechnologies (ADPT) reports revenue by business across 2 parts — Immune Medicine Business and Mrd Business. Each is extracted from the segment footnotes and tracked over time.
- Where does Adaptive Biotechnologies's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Adaptive Biotechnologies's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
